Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. In Onkológia. ISSN 1336-8176. Bratislava : SOLEN, 2016, 2016, roč. 11, č. 1, s. 57-58.